Av
Karo Bio meddelade på julafton att de tecknat ett samarbetsavtal med Pfizer om att tillsammans utveckla nya substanser för behandling av autoimmuna sjukdomar. Genom avtalet har Karo Bio möjlighet att få totalt 217 miljoner dollar, motsvarande 1,5 miljarder kronor, efter att vissa mål uppnåtts. Bolagets aktievärde ökade med 70 procent då handeln öppnade på tisdagsmorgonen efter julhelgen.
Inom ramen för forskningssamarbetet ska de båda bolagen hitta och utveckla nya småmolekylära substanser som hämmar hormonreceptorn Rorgamma. Rorgamma-receptorn är ett relativt nytt mål för läkemedelsutveckling inom autoimmuna sjukdomar. Tidigare studier har visat att receptorn styr produktionen och utsöndringen av cytokinsubstansen IL-17 som spelar en viktig roll i inflammationsprocessen vid autoimmuna sjukdomar som ledgångsreumatism, multipel skleros och psoriasis.
Karo Bio har sedan 2010 forskat kring Rorgamma-hämmande substanser och hittat nya substanser som hämmar aktiviteten i receptorn.
Pfizer kommer att stå för utvecklingskostnaderna i forskningssamarbetet. Genom avtalet får Pfizer ensamrätt till de produkter som samarbetet kan leda till. Karo Bio å sin sida får, utöver den direkta ersättningen, även rätt till royalties på framtida försäljning av eventuella läkemedel som kommer ut ur samarbetet.
- Genom att kombinera Karo Bios djupa kunnande inom nukleära receptorer med Pfizers världsledande kompetens inom kemi och cytokin-immunologi, kan våra ansträngningar att utveckla nya läkemedel inom detta konkurrensutsatta område accelerera, säger Jose-Carlos Gutierrez-Ramos, Senior vice president på Pfizer, i ett pressmeddelande.
Inom ramen för forskningssamarbetet ska de båda bolagen hitta och utveckla nya småmolekylära substanser som hämmar hormonreceptorn Rorgamma. Rorgamma-receptorn är ett relativt nytt mål för läkemedelsutveckling inom autoimmuna sjukdomar. Tidigare studier har visat att receptorn styr produktionen och utsöndringen av cytokinsubstansen IL-17 som spelar en viktig roll i inflammationsprocessen vid autoimmuna sjukdomar som ledgångsreumatism, multipel skleros och psoriasis.
Karo Bio har sedan 2010 forskat kring Rorgamma-hämmande substanser och hittat nya substanser som hämmar aktiviteten i receptorn.
Pfizer kommer att stå för utvecklingskostnaderna i forskningssamarbetet. Genom avtalet får Pfizer ensamrätt till de produkter som samarbetet kan leda till. Karo Bio å sin sida får, utöver den direkta ersättningen, även rätt till royalties på framtida försäljning av eventuella läkemedel som kommer ut ur samarbetet.
- Genom att kombinera Karo Bios djupa kunnande inom nukleära receptorer med Pfizers världsledande kompetens inom kemi och cytokin-immunologi, kan våra ansträngningar att utveckla nya läkemedel inom detta konkurrensutsatta område accelerera, säger Jose-Carlos Gutierrez-Ramos, Senior vice president på Pfizer, i ett pressmeddelande.
"We are making it more attractive for companies to invest in innovation with reduced corporation tax on profits from patents to 10%." 
"Innovation takes place when biology meets engineering; ICT is an enabler to solve the needs for increased functionality and reduced cost in Life Science" 
"Our services in ligand-based and structure-based drug design is a cost-efficient alternative for smaller pharmaceutical companies" 
"We are recognized as a flexible partner with short decision and lead times plus a proven record for the highest quality and cost efficiency." 
"Medivir is a specialty pharmaceutical company with unique positioning on the Nordic market and our goal is become a profitable company in high growth" 
"We have a unique technological platform, built around 5HT-receptor antagonism, for the treatment of inflammation and pain"." 
"To develop innovative and effective pharmaceuticals within autoimmune/ inflammatory diseases and cancer where major medical need exists" 
"Dilafor is developing new products in the field of obstetrics, to provide an effective solution to the challenge of dystocia or protracted labor"
" 
"Your global partner of pharmaceutical service and cGMP manufacturing" 
"Best in class companies see the value of optimising their business by having an effective strategy for information management and documentation." 
"Together with Zacco our clients achieve their business goals through the management of their intellectual property." 
"The PolyPeptide Group is a world class manufacturer of peptide active pharmaceutical ingredients." 
"We turn medical research into applications for better health and well-being." 
"To become an internationally leading dental company with innovative, proprietary products of high therapeutic and commercial value." 
"Our goal is to invest in innovations and develop new unique pharmaceuticals" 
"To adapt Competent Authorities´ requirements into opportunities is not just an artform - today it´s a business necessity." 
"Allenex is a life science company that develops, manufactures, markets and sells high quality products for the transplantation market." 
"We help our clients create significant business value through scientific expertise." 
"As a full service CRO with offices in all Nordic countries we can provide our customer with professional support throughout the clinical research." 
"To supply Swedish and Danish laboratories with laboratory equipment and furniture of highest quality and offer service on all delivered products." 
"Our organisation value is to contribute to positioning Scandinavian healthcare and research in absolute world class." 
"Mercodia has been a supplier of reliable assays since 1991" 
"To be acknowledged as the Best-in-Class provider of pharmaceutical development and manufacturing services by customers, employees & other stakeholders" 
"Our products enable an increased number of transplants leading to substantial cost savings for society and increased quality of life for patients." 
"We aim to be the pioneering benchmark in user-friendly software experience in combination with the highest level of quality." 
"Our aim is to be the best drug development partner to the biotechnology and pharmaceutical industry no matter where you are based." 
"TFS is today the leading European development partner for biopharmaceutical companies in their global clinical development process." 
"Your work is important to us, we are committed to your success.
Innovative tools? Please download the Promega app." 
"Novel products for CVD treatment and prevention." 
"VWR is a global laboratory distributor of chemicals, life science products, consumables, equipment, instruments, furniture, e-commerce and services" 
"Our reliability, customer service, global network and integrated technology make World Courier service truly "A service no one else can deliver"." 
"Uppsala BIO is a life science pathfinder. We build ways to make life science flourish, in cooperation with industry, academia, society and healthcare." 
"With our first class products and our committed and skilled colleagues we guarantee our customers the best support in the market, at no extra charge." 
"We promise to go the extra mile every day to ensure you receive the highest level of service and value with each shipment you entrust to us." 
"PCG - a professional full service CRO for your clinical trials.
Powered by Viedoc, globally trusted eCRF, keeping trials within budget and timelines" 
"We are entirely devoted to luminescence technology." 
"APL provides high-quality services to Life Science. We are a Dedicated Partner from Discovery to Market." 
"Discover your possibilities in one of Europe´s most productive life science regions. Welcome to Stockholm-Uppsala."
" 
"We offer effective staffing solutions provided by specialists, we understand a company’s specific needs and we know where to find the best talent." 
"Anton Paar is a product and service leader in the field of scientific instruments. We deliver uncompromised quality in everything we do." 
"To be the most attractive node and business platform in the Nordic countries for new and innovative Life Science companies" 
"Our vision is to become one of the top 10 global providers of scientific instruments; we will get there by striving for market leadership in our respective product and application niches."
" 
